Resurrection of PARP inhibitors in breast cancer Journal Article


Authors: Lyons, T. G.; Robson, M. E.
Article Title: Resurrection of PARP inhibitors in breast cancer
Abstract: PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1- and BRCA2-mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA-mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer. © JNCCN—Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-09-01
Start Page: 1150
End Page: 1156
Language: English
DOI: 10.6004/jnccn.2018.7031
PROVIDER: scopus
PUBMED: 30181424
DOI/URL:
Notes: Review -- Export Date: 1 October 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Mark E Robson
    358 Robson
  2. Tomas Gerard Lyons
    6 Lyons